Harbour BioMed and CTTQ Partner to Discover New Cancer/Immune Drugs

02:11 EDT 10 May 2019 | ChinaBio Today

Harbour BioMed will partner with Chia Tai Tianqing (CTTQ), a Lianyungang pharma, to discover and develop next-gen biologics for therapeutic targets in oncology and immunology. Harbour will use its discovery platform, including its transgenic mouse technology, to generate fully human antibodies, while CTTQ will contribute its preclinical development expertise. CTTQ will be responsible for clinical development of all candidates in China and the EU; Harbour will have rights to the US and the rest of the world. Each company will pay royalties on sales to the other. More details....

Share this with colleagues:

Original Article: Harbour BioMed and CTTQ Partner to Discover New Cancer/Immune Drugs


More From BioPortfolio on "Harbour BioMed and CTTQ Partner to Discover New Cancer/Immune Drugs"

Quick Search


Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...